Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/S1092852924002384 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Association Between Dextromethorphan/Bupropion with Alcohol and Substance Misuse: Reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).
CNS Spectr
October 2024
Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada.
Objective: Dextromethorphan/bupropion (DXM/BUP) received Food and Drug Administration (FDA) approval for the treatment of adults with major depressive disorder (MDD) in August 2022. This combination is not known to have abuse liability and is not currently scheduled by the Drug Enforcement Administration (DEA). Notwithstanding, dextromethorphan is a drug of abuse.
View Article and Find Full Text PDFSAL0114: a novel deuterated dextromethorphan-bupropion combination with improved antidepressant efficacy and safety profile.
Front Pharmacol
September 2024
The Guangdong Provincial Key Laboratory of Cardiovascular Drug R and D Enterprises, Shenzhen Salubris Pharmaceuticals Co., Ltd., Shenzhen, Guangdong Province, China.
Article Synopsis
- Esketamine is the first fast-acting antidepressant approved by the FDA but has limited use due to addiction risks; SAL0114 is a new formulation aiming to improve safety and efficacy by combining deuterated dextromethorphan with bupropion.
- Research methods included binding assays to evaluate the effects of deuteration, stability tests in mice, and various animal models to assess antidepressant effects.
- Results showed that deuterated dextromethorphan had double the metabolic stability of regular dextromethorphan and worked synergistically with bupropion, leading to superior effectiveness in treating depression.
Brexpiprazole for Agitation Associated With Dementia Due to Alzheimer's Disease.
J Am Med Dir Assoc
October 2024
Alzheimer's Disease Care, Research and Education (AD-CARE), Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA. Electronic address:
Alzheimer's disease (AD) is a prevalent neurodegenerative disease characterized by progressive cognitive and functional decline. Nearly all patients with AD develop neuropsychiatric symptoms (NPSs). Agitation is one of the most distressing and challenging NPS.
View Article and Find Full Text PDFPharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape.
Am J Psychiatry
March 2023
Center for Depression Research and Clinical Care, Department of Psychiatry, UT Southwestern Medical Center, and O'Donnell Brain Institute, UT Southwestern Medical Center, Dallas (Jha); Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston (Mathew); Michael E. DeBakey VA Medical Center, Houston (Mathew); Menninger Clinic, Houston (Mathew).
Article Synopsis
- One in three adults with major depressive disorder (MDD) experience treatment-resistant depression (TRD), which significantly impacts their health and leads to higher healthcare costs.
- The report focuses on atypical antipsychotics approved for treating depression, noting that while they can improve symptoms, achieving full remission remains challenging and side effects are a concern.
- There’s a need for pragmatic clinical trials to compare atypical antipsychotics with newer treatments and establish the best treatment sequences, emphasizing shared decision-making between clinicians and patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!